DOK2 has tumour suppression roles in several cancer types as it impairs MAPK activation and loss of its expression is associated with poor survival in lung adenocarcinoma [51], whilst in BCa greater DOK2 expression is associated with significantly longer disease free survival [52]. This evidence concerns the gene DOK2 and lung adenocarcinoma.